Irbesartan

Onye na-ahụ maka antihypertensive, otu ihe nnabata angiotensin II na-abụghị asọmpi antagonist (ụdị AT1). Na-egbochi mmetụta vasoconstrictor nke angiotensin II ma belata ntinye nke aldosterone na plasma ọbara. Ọ naghị egbochi kinase II - enzyme nke na-ebibi bradykinin. OPSS na -ebelata, belata mgbe ibuchara, belata usoro ọbara mgbali na nrụgide na mgbasa akwara. Mmetụta kasịnụ na-etolite n'ime awa 3-6 mgbe ị doseụ otu ọgwụ. The antihypertensive mmetụta na-adịgide ruo awa 24. A na-enweta mmetụta na-adakarị ụlọ ọgwụ mgbe izu 1-2 gachara iji irbesartan. Mgbe ịkwụsị ọbara ọgbụgba na-amaliteghachi nwayọọ nwayọọ na ọkwa ya. Irbesartan emetụtaghị mkpokọta nke TG, ọkwa nke cholesterol, glucose, uric acid na plasma ọbara ma ọ bụ mpụta nke uric acid na mmamịrị.
Mgbe nchịkwa ọnụ gasịrị, ọ na-etinye obi gị dum na ngọngọ nri. Mkari nke irbesartan na plasma ọbara ka eruola mgbe awa 1.5-2 gachara. Bioavailability bụ 60-80%. Iri nri ugbua anaghị emetụta ndu. Ijikọ protein na ihe dị ka 90%. A na-emegharị Irbesartan n'ime imeju n'ihi njikọta nke glucuronide yana n'ihi oxidation. Ihe bụ isi metabolite bụ irbesartan glucuronide (ihe dị ka 6%). Oge iwepu ọkara ndụ bụ awa iri na isii 11. N'ime ndị ọrịa nwere ọria imeju na / ma ọ bụ ọrụ akụrụ, a naghị agbanwe oke ọgwụ pharmacokinetic nke irbesartan.

Ojiji Irbesartan nke ọgwụ ahụ

Ọgwụ mbụ bụ 150 mg otu ugboro n'ụbọchị, mgbe ahụ enwere ike ịbawanye dose ahụ gaa na 300 mg otu ugboro n'ụbọchị, were nri ma ọ bụ na afọ na-enweghị isi. Ọ na-atụ aro ka ị were ụbọchị niile n'otu oge. Y’oburu n’ahoghi ogwu, ogwu ubochi ozo ekwesighi okpukpu abuo. Ngwakọta ọgwụ na irbesartan na mgbakwunye na diuretics (hydrochlorothiazide) ma ọ bụ ọgwụ ndị ọzọ antihypertensive ga-ekwe omume.

Ntụziaka pụrụ iche maka ị Irụ ọgwụ Irbesartan

Ọrịa dị elu tupu irbesartan nwere ike ibute akpịrị ịkpọ nkụ ma mee ka ohere nke hypotension dịkwuo ná mmalite nke ọgwụgwọ. Site na oke akpịrị ịkpọ nkụ ma ọ bụ hyponatremia n'ihi ọgwụgwọ diuretic kpụ ọkụ n'ọnụ, nri hyponatrium, afọ ọsịsa ma ọ bụ vomiting, yana ndị ọrịa na hemodialysis, ọgwụ irbesartan kwesịrị ibelata.
Ọ bụrụ na ọ dị mkpa, nha nke irbesartan n'oge inye nwa ara ga-ekpebi nkwụsị nke ị breastụ ara. Emebeghi nchekwa na ike nke irbesartan n'ime ụmụaka.

Ọgwụ Farmacology

Kpamkpam nke na anagaghị egbochi ndị nnabata angiotensin II (ụdị nke AT)₁) Na -ebilata nsonaazụ vasoconstrictor nke angiotensin II, na-ebelata itinye uche nke aldosterone na plasma, belata OPSS, ibubata obi, usoro ọbara mgbali na nrụgide na mgbasa akwara. Nke a anaghị emetụta kinase II (ACE), nke na-emebi bradykinin ma na-etinye aka na nguzobe nke angiotensin II. Ọ na - arụ ọrụ nwayọ, mgbe otu ngale gachara, nsonaazụ kachasị na - ebilite mgbe awa isii 6. Mmetụta antihypertensive na - adịgide ruo awa 24. Mgbe ejiri ya na - eme izu 1-2, ọ na - enwe mmetụta ọ ga - akwụsi ike ma rute karịa mgbe izu 4-6 gasịrị.

Ngwa ngwa, ewepu nri na ngụgụ, ọnụego mwepụ bụ nnagide oriri. Bioavailability - 60-80%, C_max kpebisiri ike mgbe awa 1.5-2. Enwere mmekọrịta kwụsịrị n’etiti irbesartan na ntinye ya n’ọbara (n’ogo nke 10-6 mg). Ekwesịrị itinye uche plasma plasma n'ime ụbọchị 3 mgbe mmalite ọgwụgwọ. Mkpoko protein Plasma bụ 96%, olu nkesa bụ 53–93 L, mkpokọta Cl bụ 157-176 / min, renal Cl bụ 3-3.5 ml / min. Ọ na - enyocha biotransformation na imeju site na iji mmiri na - esonye na isoenzyme CYP2C 9 nke cytochrome P450 na conjugation na - esote ya na nguzobe metabolites na - adịghị arụ ọrụ, ihe bụ isi bụ irbesartan glucuronide (6%). Ndi_1/2 - Nkeji 11-15. N’ime akụrụ (20%, nke ihe na-erughi 2% agbanweghi) na imeju.

Nlekọta ụmụ anụmanụ (oke, macaques) na oke ọnụọgụ (karịa 500 mg / n'arọ / ụbọchị) na-esonyere mmepe nke mgbanwe ngbanwe na akụrụ (interstitial nephritis, ịgbasa tubular na / ma ọ bụ basophilic infiltration nke renal tubules, ịba ụba nke uric acid na creatinine na plasma) na mbelata gbasara akụrụ. Na usoro onunu gafere 90 mg / kg / ụbọchị (oke) na 110 mg / kg / ụbọchị (macaques) na - akpata sel ọbara (hyperplasia) mkpụrụ ndụ juxtaglomerular.

N'okpuru ọnọdụ ogologo oge (afọ abụọ) nchịkwa ka anụmanụ nwere nnwale na doses karịrị MPD, ugboro 3 (oke oke), ugboro 3-5 (ụmụ oke na ụmụ oke) na oge 21 (oke oke) enweghị mkpụrụ ọgwụ na-achọpụta. N'ime nyocha nke ụdị ọgwụ ọjọọ ndị ọzọ akọwapụtara, achọpụtaghị ọrụ mutagenic na teratogenic.

Nsonaazụ nke ihe Irbesartan

Site na ụjọ na akwara anụ ahụ: ≥1% - isi ọwụwa, ọgbụgbọ, ike ọgwụgwụ, nchekasị / ikerechi.

Site na sisitemu obi na obara (hematopoiesis, hemostasis): ≥1% - tachycardia.

Site na usoro iku ume: ≥1% - ọrịa akụkụ azụ na-efe efe (fever, wdg), sinusopathy, sinusitis, pharyngitis, rhinitis, ụkwara.

Site na ngwara: ≥1% - afọ ọsịsa, ọgbụgbọ, ọgbụgbọ, ọrịa dyspeptik, obi mgbawa.

Site na usoro mọzụlụ: ≥1% - olu mgbu (gụnyere myalgia, ihe mgbu na ọkpụkpụ, na obi).

Mmeghachi omume nfụkasị ahụ: ≥1% - nsogbu.

Ndị ọzọ: ≥1% - mgbu n’ime oghere afọ, ọrịa urinary tract.

Mmekorita

Diuretics na ọgwụ ndị ọzọ na - egbochi mkpali. Thiazide diuretics na-akwalite mmetụta ahụ. Ọgwụ tupu a gwọọ ya n’ọrịa dị elu nwere ike ibute akpọnwụ akpukpo ma mee ka ohere nke hypotension pụta na mbido ọgwụgwọ na irbesartan. Irbesartan dakọtara na ọgwụ ndị ọzọ na - egbochi ọgwụ (beta-blockers, ndị na - egbochi calcium channel).

Ihe mgbakwunye potassium na-eme ka ọnụọgụ potassium na-adị. Na-abawanye n'ihe ize ndụ nke hyperkalemia mgbe ejiri ya na ọgwụ mkpịsị ọkụ na potassium.

Lithium: enwere mmụba nke mgbanwe lithium ndọba ma ọ bụ ihe na-egbu egbu jiri ya mee ihe na ojiji nke lithium na angiotensin na-agbanwe ntụgharị enzyme. N'ihe banyere irbesartan, ụdị mmetụta a adịkarịghị ụkọ ruo taa, mana a na-atụ aro iji nlezianya nke ọkwa lithium n'oge iji ọgwụ eme ihe n'otu oge.

NSAIDs: na nchịkwa nke angiotensin II antagonists na NSAIDs (dịka ọmụmaatụ, ndị na - ahọpụta COX-2 inhibitors, acetylsalicylic acid> 3 g / day na NSAIDs na - abụghị nhọrọ), mmetụta nwere ike ịdalata ike.

Dị ka ọ dị na ndị na - egbochi ACE, ijikọ ndị antagonensin II antagonists na NSAIDs nwere ike ịbawanye ihe ize ndụ nke ọrụ na-akpata nsogbu, gụnyere ohere nke nnukwu gbasara akụrụ, na ịbawanye ọkwa potassium, karịsịa na ndị ọrịa nwere arụ ọrụ ezumike arụrịrị ọrụ. Site na ntinye nke ngwakọta a, ekwesịrị ịkpachara anya, karịsịa na ndị ọrịa agadi. Ọ dị mkpa ka ndị ọrịa na-arụ mmiri kwesịrị ekwesị ma nyochaa ọrụ akụrụngwa n'oge usoro njikọta yana mgbe oge ọ gwụchara.

Hydrochlorothiazide. Aclọ ọgwụ ọgwụ irbesartan anaghị agbanwe agbanwe mgbe ejikọtara ya na hydrochlorothiazide.

Ihe a na-ahụ anya nke Irbesartan bụ ntinye aka nke CYP2C9 na, ruo ntakịrị obere, glucuronidation. Enweghi mmekorita ọgwụ ma ọ bụ ọgwụ ọgwụ dị mkpa na ntanetị nke irbesartan na warfarin, ọgwụ CYP2C9 mejupụtara. Enyochabeghị mmetụta CYP2C9 na-akpali akpali dị ka rifampicin na ọgwụ ọgwụ nke irbesartan.

Irbesartan anaghị agbanwe ọgwụ ọgwụ digoxin.

Kpachara anya maka ihe Irbesartan

A na-eji nlezianya mee ya na ndị ọrịa nwere hyponatremia (ọgwụgwọ ya na diuretics, igbochi oriri nnu na nri, afọ ọsịsa, vomiting), na ndị ọrịa na hemodialysis (mmepe nke hypotension hypotension ga-ekwe omume), yana ndị ọrịa akpịrị. Ekwesịrị iji nlezianya gosipụta ndị ọrịa nwere ọbara mgbali elu n'ihi akwara azụ akwara stenosis ma ọ bụ akụrụ akwara stenosis nke otu akụrụ (ohere dị ukwuu nke hypotension na akụrụ siri ike), aortic ma ọ bụ mitral stenosis, mgbochi mkpụrụ obi na-egbochi ọbara ọgbụgba, nnukwu obi ike (ọkwa III III). NYHA) yana ọrịa obi na-arịa ọrịa obi (oke nsogbu nke infarction myocardial infarction, angina pectoris). Megide ndabere nke ọrụ akụrụma nwere nsogbu, a na-atụ aro ileba anya nke potassium potassium na ọkwa creatinine. A naghị akwado ya maka ndị ọrịa nwere hyperaldosteronism nke mbụ, yana nnukwu akwara na-ada mba (enweghị ahụike na-adakarị), na ndị ọrịa nwere mmịnye akụrụ na nso nso a (enweghị ahụike ọhụụ)

Mwepụta wepụtara ya na ihe mejupụtara

Irdị Irbesartan na -emepụta bụ mbadamba ihe eji eme fim: biconvex, okirikiri, shei na isi ya dịcha ọcha ma ọ bụ na-acha ọcha (na ngwugwu ọnya nke 3, 4, 7, 10, 14, 15, 20, 25 ma ọ bụ 30,, na igbe kaadi. A na-etinye akwa 1-8 ma ọ bụ 10, na Mkpọ nke polyethylene terephthalate 10, 14, 20, 28, 30, 40, 50, 60 ma ọ bụ 100 na igbe kaadiboodu, enwere ike itinye 1).

Ngwakọta nke mbadamba 1 gụnyere:

• ihe na-arụ ọrụ: irbesartan - 75, 150 ma ọ bụ 300 mg,
• ihe ndị ọzọ (75/150/300 mg): microcrystalline cellulose - 24/48/96 mg, lactose monohydrate (shuga mmiri ara ehi) - 46.6 / 93.2 / 186.4 mg, colloidal silicon dioxide - 0.8 / 1 , 6 / 3.2 mg, ssumum croscarmellose - 7.2 / 14.4 / 28.8 mg, magnesium stearate - 1.6 / 3.2 / 6.4 mg, povidone-K25 - 4.8 / 9, 6 / 19.2 mg
• shei (75/150/300 mg): titanium dioxide - 1.2 / 2.4 / 4.8 mg, macrogol-4000 - 0.6 / 1.2 / 2.4 mg, hypromellose - 2.2 / 4 4 / 8.8 mg.

Mlọ ọgwụ

Irbesartan, ịbụ onye na - ahọ ụta nke ndị na - anabata angiotensin II (ụdị AT1), na - enyere aka iwepụ vasoconstrictor mmetụta nke angiotensin II, belata nsị plasma nke aldosterone n'ime ọbara (na - enweghị iwepụ kinase II. , mgbe ebidochara mgbali na mgbasa akwara. Ọ dịghị emetụta mkpokọta plasma nke cholesterol, triglycerides, glucose, uric acid na mpụta nke uric acid.

A na-enweta mbelata ọbara mgbali elu mgbe awa 3-6 gachara ọgwụ nchịkwa nke ọgwụ ahụ, a na-eme ka mmetụta antihypertensive dịkarịa ala awa 24. Afterbọchị mgbe nchịkwa ahụ, mbelata ọbara mgbali elu bụ 60-70% ma e jiri ya tụnyere mbelata kachasị na nrụgide diastolic / systolic na nzaghachi ị theụ ọgwụ ahụ. Mgbe ị na-ewere 150-300 mg 1 oge kwa ụbọchị, ogo nke Mbelata ọbara ọgbụgba na njedebe nke etiti interdose (ya bụ, awa 24 mgbe ị theụsịrị ọgwụ ahụ) na ọdụ onye ọrịa ma ọ bụ dina n'akụkụ dị ka 5-8 / 8-13 mm Hg. Art. (n'otu n'otu) karịa placebo. Nzaghachi antihypertensive site na ị takingụ ọgwụ ahụ na ọgwụ nke 150 mg 1 oge kwa ụbọchị adịghị iche na iji ọgwụ a na usoro 2. Mmetụta antihypertensive nke irbesartan na-etolite n'ime izu 1-2, a na-enwetakwa ọgwụgwọ kachasị na-apụta mgbe izu isii na isii site na mmalite ọgwụgwọ. Mgbe ịkwụsị ọgwụ ahụ, ọbara mgbali ji nwayọọ nwayọọ na-alaghachi uru mbụ ya, na-enweghị mmepe nke ọrịa mwepụ. Iji nweta nsonaazụ antihypertensive, ọgwụgwọ dị ogologo oge dị mkpa.

Irdị irè nke irbesartan adịghị adabere na nwoke na nwanyị.

Ndị ọrịa nke agbụrụ Negroid anaghị anabata ọgwụ monotherapy na ọgwụ ahụ.

Mlọ ọgwụ

Mwepu: a na-agbaso Irbesartan ma a gwaa ya nke ọma site na eriri afọ. Oke plasma ịta ọbara ka erute mgbe awa 1.5-2 gachara nchịkwa ọnụ, ihe ngosipụta bioavailability zuru oke bụ 60-80%. Iri nri anaghị emetụta oke bioavailability. Irbesartan nwere onodu ogha na linear pharmacokinetics na onodu ogwu nke 10-600 mg, na onunu ogwu di elu (ugboro abuo kariri ihe aturu aro ya), kinetik nke ihe ahu gh’abeghe.

Nkesa: njikọ nke ihe n’ime protein ndị na - arụ ọrụ plasma bụ ihe dịka 96%. Jikọtara ihe ndị mejupụtara ọbara ọbara abaghị uru. Olu nke nkesa bụ lita 53,33. E mejupụtara ịha n ’ịta ụta nwere otu ụbọchị kwa ụbọchị rue ụbọchị atọ. Site na usoro onunu ogwu ugboro ugboro, enwere obere mkpokoro nke ihe ahụ na plasma ọbara (isi iteghete na mkpokọta -mụaka).

Mmechi (ọrịa / ọnọdụ ọnụnọ nke nchịkwa nke Irbesartan chọrọ ịkpachara anya):

• ike obara nke obara,
• mitral / aortic valve stenosis,
• hyponatremia,
• hypovolemia,
• rube isi na nri nwere obere nnu,
• afọ ọsịsa, vomiting,
• ọnụọgụ abụọ
• na - eme ka akwara kpụrụ akpụ akụrụ,
• akwara obi na ọrịa obi na / ma ọ bụ ọnya akwara nke arịa ụbụrụ,
• adịghị ala ala nke III - IV klaasị arụmọrụ dị ka nhazi NYHA,
• gbasara akwara
• hyperkalemia
• ọnọdụ mgbe akụrụ akụrụ,
• ịba ọcha n'anya
• hyperaldosteronism,
• ngwakọta ọgwụgwọ na diuretics,
• jikọtara ya na ọgwụ mgbochi na-abụghị steroidal, gụnyere cyclooxygenase II inhibitors, angiotensin-na-agbanwe enzyme inhibitors ma ọ bụ aliskiren,
• gbara afọ iri asaa na ise.

Ntuziaka maka iji Irbesartan: usoro na usoro onunu ogwu

A na-ewere Irbesartan ọnụ, na-elo mbadamba nkume niile na mmiri ọ drinkingụ .ụ. Nwere ike iji ọgwụ ahụ n'agbanyeghị oge nri.

Usoro mbụ / mmezi bụ 150 mg otu ugboro kwa ụbọchị (ọ na - enye njikwa ọbara mgbali elu ụbọchị, n'ụfọdụ, ọ kachasị ndị ọrịa na hemodialysis, ma ọ bụ na ndị ọrịa kariri afọ 75, ọgwụ mbụ bu 75 mg). Ọ bụrụ na enweghị ọgwụgwọ ọgwụgwọ, enwere ike ịbawanye dose ahụ site na ugboro abụọ.

N'ihe banyere mbelata ọbara mgbali ezughi oke dị ka monotherapy, diuretics ma ọ bụ ndị ọzọ na - egbochi ihe mgbochi nwere ike ịgbakwunye na Irbesartan.

Site na ọbara mgbali elu na ụdị ọrịa shuga abụọ nke ọrịa mellitus, a ga-amalite usoro ọgwụgwọ na 150 mg otu ugboro kwa ụbọchị ma jiri nwayọọ nwayọọ mụbaa ruo 300 mg - dose nke kachasị mma na ọgwụgwọ nke nephropathy.

Mkparịta ụka ọgwụ ọjọọ

Site na iji Irbesartan jikọtara ya na ụfọdụ ọgwụ / ọgwụ, mmetụta ndị a nwere ike ịmalite:

• ọgwụ nwere aliskiren: ọgwụ a contraindicated na ndị ọrịa na-arịa ọrịa shuga mellitus ma ọ bụ na agafeghị oke / oké gbasara akụrụ odida, na ndị ọrịa ndị ọzọ na-adịghị atụ aro ya,
• angiotensin na-atụgharị ndị na - egbochi enzyme: a na - akwado ọgwụ a n'ahụ ndị ọrịa nwere ọrịa nephropathy, ndị ọrịa ndị ọzọ akwadoghị ya,
• ọnya ụkwara (ọgwụ ụgwụ n'oge a na-a highụ ọgwụ dị elu): akpọnwụ akpịrị na ohere nke hypotension ike na mbido ojiji nke Irbesartan,
• diuretics na ihe ndị ọzọ na - egbochi ọgwụ (antihypertensive effect): ike na - arụ ọrụ antihypertensive (ikekwe usoro ọgwụgwọ na - egbochi ọgwụ β-adrenergic, ndị na - eme ngwa ngwa ndị na - egbochi calcium na thiazide diuretics),
• Nkwadebe nke lithium: mmụba nke okpukpo lithium ọbara n'ime ọbara ma ọ bụ nsị ya (ọ bụrụ na ọ dị mkpa, ijikọ ọnụ na-achọ nlezianya nke nlebara lithium),
• nhazi nke potassium, ihe ngwọta mmiri nke nwere potassium, na - eme ka ọnụọgụ nke potassium, ọgwụ ndị nwere ike ịbawanye ọdịnaya potassium n'ime ọbara, gụnyere heparin: mmụba nke potassium ọbara n'ọbara,
• ọgwụ mgbochi anaghị egbu ọgwụ: na-ebelata mmetụta antihypertensive nke irbesartan, ịbawanye ohere nke nsogbu akụrụ, tinyere ihe ọghọm nke nnukwu akụrụ na-ada ada, yana ịba ụba ụrọ nke ọbara, ọkachasị na arụ ọrụ ezigharịrị mkpali (njikọta ahụ chọrọ ịkpachara anya, ọkachasị ndị agadi ọrịa yana hypovolemia , ịkwesịrị iweghachi olu nke na-ekesa ọbara n'oge oge ọgwụgwọ a na-ejikọ ọnụ, yana oge ụfọdụ mgbe ọ gasịrị Akwụsị a, nyochaa gbasara akụrụ ọrụ).

Analogs nke Irbesartan bụ: Aprovel, Firmasta, Ibertan, Irsar, wdg.

Nyocha na Irbesartan

Dabere na nyocha, Irbesartan bụ otu n'ime ọgwụ ndị a na-enweta maka ọgwụgwọ ogologo oge nke ọbara mgbali nwayọọ nwayọọ / na-agbanwe agbanwe. Achọpụtakwara arụmọrụ ya na oke ọbara mgbali elu (yana ọgwụ kwa ụbọchị nke 300 mg) yana mmụba nke ọbara mgbali n’abalị. Ọgwụ ahụ, dị ka a na-achị, na-anabata nke ọma ma na-eduga n'ịzụlite nsonaazụ (ọkachasị n'ụdị adịghị ike na anya mmiri) naanị n'ọnọdụ ndị a na-adịghị ahụkebe.

Enwere nyocha na arụmọrụ Irbesartan megide ọrịa shuga na ọrịa nephropathy.

Ihe ngbanwe

• afọ ruo afọ 18
• hypersensitivity
• tụụrụ ime,
• inye ara.

Eji nlezianya tụọ mgbe aortic valve stenosis, CHF, akpịrị ịkpọ nkụ, afọ ọsịsavomiting hyponatremia, stenosisgbasara akwara (ịdị n'otu na ọnụọgụ abụọ).

Irbesartan, ntuziaka maka ojiji (Usoro na usoro onunu ogwu)

Mbadamba ụrọ na-ewere ọnọdụ dị na afọ na-enweghị ihe ọ bụla ma ọ bụ jiri nri jupụta nke ọma. Bido ọgwụgwọ na 150 mg kwa ụbọchị. Ọgwụ a na-enye njikwa kachasị mma n'oge ụbọchị ma e jiri ya tụnyere 75 mg / ụbọchị.

Nke a, ha na-abawanye ruo 300 mg kwa ụbọchị, mana ọ nweghị ihe ọzọ, ebe ọ bụ na mmụba ọzọ anaghị eduga na mmụba nke mmetụta hypotensive. N'okwu a, a na-atụ aro ka ịgbakwunye diuretics. N'ime ndị ọrịa gbagoro afọ 75, na ndị ọzọ ịba ọcha n'anya ya na akpịrị ịkpọ nkụ ịmalite ọgwụgwọ na 75 mg, dị ka Symptomatic hypotension akwara. Na ndị ọrịa na- gbasara akwara chọrọ ịchịkwa ịta creatinine na potassium n'ime ọbara. Na siri ike CH ịbawanye n'ihe egwu azotemia na oliguriana kadioyopathies - ihe egwu infarction myocardial. Nyere ọgwụgwọ ahụ kwere omume anya ntughari na ike ọgwụgwụ, kpachara anya mgbe ị na-anya ụgbọala.

Dodoụbiga ya ókè

Eweputara tachycardia ma obu bradycardiaibelata ọbara mgbali, ida. Ọgwụgwọ na-amalite site na lavage gastric na ichekwa. carbon na-arụ ọrụ. Ihe ndị a bụ usoro ọgwụgwọ Symptomatic.

Ngwakọta na ụdị ntọhapụ

A na-azụ ahịa ọgwụ a n'ụdị nke mbadamba mkpuchi. Ihe kachasị dị mkpa nke ọgwụ ahụ bụ irbesartan n'onwe ya. Ọgwụ a bụ ọgwụ ọgwụ antihypertensive. Irbesartan adịghị ọnụ. N'ime ụlọ ahịa ọgwụ, dabere na onye na-ebubata ya, enwere ike ịzụta ya maka 260-300 p. (Mbadamba 28).

Ihe ngosi na contraindications maka ojiji

Analogs nke Irbesartan, ntuziaka maka ojiji nke a ga-atụle n'okpuru, enwere ike ịkọwa ya kama ị insteadụ ọgwụ a ma ọ bụrụ na ekweghị anabata onye ọrịa nke ihe mejupụtara ya ma ọ bụ na ọ gaghị ekwe omume inweta ya n'ihi enweghị ụlọ ahịa ọgwụ. N'ime edemede ahụ anyị ga-ekwu maka ndị dochie maka ngwaọrụ a. Ugbu a, anyị ga-aghọta ihe ọgwụ a n’onwe ya bụ, na otu esi ewere ya nke ọma.

Edere ọgwụ a maka isi ọbara mgbali elu. Mgbe ụfọdụ, a na-enye ya akwụkwọ maka sekọndrị. Ọzọkwa, ọgwụ ahụ nwere ike ịba uru n'ahụ ndị ọrịa nwere ọrịa dịka nephropathy nwere ọrịa shuga 2 na oke ọbara. Agbanyeghị, na nke a, a na-eji ọgwụ "Irbesartan" eme ihe naanị na njikọta ọgwụ ndị ọzọ.

Enweghị ọgwụ mgbochi ụfọdụ akọwapụtara maka ọgwụ a. Nweghị ike iwere ya naanị ndị ahụ ihe nfụkasị ọ bụla. Agbanyeghị, iji ọgwụ a akwadoghị ụmụ nwanyị dị ime na ndị na-enye nwa ara, ụmụaka na-erubeghị afọ 18. N'ọnọdụ ụfọdụ, ekwesịrị iji nlezianya mee ọgwụ a. N'okpuru nlekọta ahụike dị nso, ha na-a itụ ya, dịka ọmụmaatụ, na ọrịa ndị dị ka hyponatremia na akpịrị ịkpọ nkụ.

Kedu ihe ọghọm dị na ya nwere ike inwe

Ojiji nke "Irbesartan" ga - ekwe omume naanị dịka onye dọkịta gwara ya. N'ime ụlọ ahịa ọgwụ, a na-ere ngwa a site na ndenye ọgwụ. Mmetụta Irbesartan nwere ike inye ọtụtụ. Dịka ọmụmaatụ, onye ọrịa nwere ike inweta nsogbu ndị a:

isi ọwụwa ma ọ bụ nkụda mmụọ,

na-efe efe na-efe efe, rhinitis na ahụ ọkụ,

afọ ọsịsa, obi mgbu, ọgbụgbọ na ọgbụgbọ,

Oge ụfọdụ ọgwụ a na-enyekwa mmetụta ọjọọ dịka ọrịa urinary tract ma ọ bụ mgbu afọ.

Kedu ka ọgwụ si arụ ọrụ?

Ọgwụ ahụ Irbesartan na-agbari ma na-agbari ngwa ngwa ma dịkwa mma. Ngwakọta ọrụ ya na-erute uche ya kachasị na plasma ọbara mgbe awa 1.5-2 gachara. N'ime ahụ onye ọrịa, ọgwụ a na - egbochi ndị na - anabata ndị na - anabata AT1, na - ebelata mmetụta ndu nke agiotensin II, na - akpali ntọhapụ nke aldosterone ma na - eme ka usoro ụjọ ahụ ọmịiko. N'ihi ihe a niile, onye ọrịa nwere mgbada ọbara na-ebelata.

Apụrụ ọgwụ a site na ahụ onye ọrịa nwere mmamịrị na bile.

Ihe atụ kachasị mma nke Irbesartan

Ọ bụrụ na enwere ọgwụ mgbochi maka ị theseụ ọgwụ ndị a ma ọ bụ maka ihe ọ bụla ọzọ, dọkịta ahụ nwere ike ịkọwa dochie anya onye ọrịa ahụ. Ọtụtụ mgbe, a na-eji ọgwụ ndị nwere ụdị ọgwụgwọ ahụ, dị ka Aprovel, Valzan, Losartal, ma ọ bụ Irsar mee ihe maka ọgwụgwọ.

Ihe atụ ndị a niile nke Ibersartan nwetara ezigbo nyocha site n'aka ndị ọrịa na ndị dọkịta.

Ọgwụ Aprovel: ụdị ntọhapụ na ngosipụta

Ngwakọta kachasị na ọgwụ a bụ irbesartan. Nke ahụ bụ, n'eziokwu, ọ na-ezo aka na nmekọ nke ụzọ anyị kọwara. Ihe ngosi maka iji ogwu a bu otu ihe a si di ya na ndi Irbesartan. Jiri ya maka isi ọbara mgbali elu na nephropathy yana njikọ ndị ọzọ. Mmetụta ndị ọ na-enwe n’akụkụ ya na nke ndị Irbesartan. Edere ọgwụ a na otu usoro onunu ogwu.

Ọtụtụ analogues nke nyocha ime Irbesartan kwesịrị mma. Mana echiche kachasị mma n'etiti ndị ọrịa na ndị dọkịta bụ ihe dochie anya Aprovel. Ogwu a di ezigbo onu karia Irbesartan. Maka mbadamba 28 nke ngwaọrụ a ga-akwụ 550-650 p. Ka osila dị, ọgwụ ahụ bụ nke ụlọ ọrụ French ama ama Sanofi-Winthrop. Nke ahụ bụ, n'eziokwu, bụ akara eji dochie anya Irbesartan.

Ọgwụ "Irsar"

Ndị dọkịta na-edepụta analogue a maka ọbara mgbali dị oke mkpa oge ụfọdụ. Ihe dị n’ime ya bụ irbesartan. A na-azụ ahịa ọgwụ a n'ụdị nke mbadamba mbadara ọfụma. Ihe ngosi, contraindications na ntuziaka maka iji ya mee ihe adighi iche na Irbesartan. Ogwu a di ihe ruru 350-450 p. maka mbadamba 28. Mana mgbe ụfọdụ n’ụlọ ahịa ọgwụ, a na-enye ya maka 600-650 r.

Ọgwụ "Valzan"

Ihe analogs ahụ nke Irbesartan nke akọwapụtara n’elu bụ nke enyere otu udiri arụ ọrụ ahụ. Mana ogwu a nwere ndi ozo edochi anya ya. Ihe ndị dị mkpa na ọgwụ ahụ bụ "Valzan", dịka ọmụmaatụ, bụ hydrochlorothiazite na valsartan. A na-enye ọgwụ a n'ahịa ka ọ bụrụ n'ụdị mbadamba ihe na blisters. Kama Irbesartan, enwere ike ịkọ ya maka ọbara mgbali elu. Ọzọkwa, ihe ngosi maka iji ọgwụ a bụ nkụchi obi na nkụchi obi na-adịghị ala ala.

Cannweghị ike iwere "Valzan" maka ọrịa imeju siri ike, ịtụrụ ime, mgbe ị na-enye nwa ara. Ọzọkwa, enyeghị ọgwụ a maka ụmụaka na-erubeghị afọ 18. Mmetụta dị iche iche nke ọgwụ a nwere ike inye ihe fọrọ nke nta ka ọ bụrụ Irbesartan. Ọgwụ "Valzan" adịghị ọnụ. Maka mbadamba 30 nke ngwaahịa a na ụlọ ahịa ọgwụ ị ga-akwụ ụgwọ banyere 15-20 p.

Uzo mbu nke ogwu a bu 80 mg otu ugboro kwa ubochi. N'ime izu abụọ na-esote, ọ na-abawanye ruo 160 mg kwa ụbọchị. N'okwu kachasị njọ, onye ọrịa ahụ nwere ike iwe ihe ruru 320 mg kwa ụbọchị.

Ọgwụ "Losartan"

Enwere ike ịzụta ụfọdụ analogues nke Irbesartan na Russia dị ọnụ ala. Nke a metụtara ọ bụghị naanị ọgwụ Valzan, kamakwa, dịka ọmụmaatụ, ọgwụ Lozartan. Ọ bụkwa ezigbo ihe eji dochie anya Irbesartan. Ngwakọta bụ isi na - arụ ọrụ na ọgwụ a bụ losartan potassium. A na-emepụta ọgwụ ahụ na mbadamba mkpuchi. “Losartan” ka a ga-edenye ndị ọrịa nwere ọria ọbara mgbali elu, obi na -akpata ọrịa, na n'ọnọdụ ndị ọzọ.

Ọgwụ a nwere ọgwụ mgbochi ụfọdụ karịa ọgwụ ndị akọwapụtara n’elu. Na mgbakwunye na ịtụrụ ime na oge nwata, ọgwụ a ekwesịghị ị drunkụ mmanya, dịka ọmụmaatụ, nwere akpịrị mmiri, ọdịda akụrụ siri ike, n'otu oge ahụ Aliskiren. Ọgwụ a na-efu 60-100 rubles na ahịa maka ngwugwu nke mbadamba 30.

Echiche nke ndị ọrịa gbasara ọgwụ "Irbesartan"

Ya mere, anyị chọpụtara ihe nkwadebe Irbesartan n'onwe ya na-anọchite anya (ntuziaka maka ojiji, analogues). Nyocha banyere ọgwụ a bụ naanị ezigbo. Nrụgide ahụ na-ebelata ọgwụ nke ọma. Agbanyeghị, iwere ya iji nweta nsonaazụ kacha mma, dịka ọtụtụ ndị ọrịa si kwuo, kwesịrị ịbụ ogologo oge.

Mpempe usoro onunu ogwu

Mbadamba ihe eji etinye ihe nkiri 75 mg, 150 mg ma ọ bụ 300 mg

Otu mbadamba ihe

ike ihe irbesartan - 75 mg ma ọ bụ 150 mg, ma ọ bụ 300 mg

n'imeonye inyeakasbekeemana: microcrystalline cellulose PH 101, calcium carmellose, povidone K-30, silicon dioxide colloidal anhydrous, calcium stearate, mmiri dị ọcha.

ihe mebere shei: Opadry white OY-S-38956, mmiri dị ọcha

mejupụtara opadry ọcha OY-S-38956: hypromellose, titanium dioxide E171, talc.

Mbadamba ụrọ a kpụrụ akpụ, ya na biconvex dị n’elu ala, nwere ihe mkpuchi na-acha ọcha ma ọ bụ ihe fọrọ nke nta ka ọ bụrụ nke na-acha ọcha na ihe osise "158" n'otu aka na "H" n'aka nke ọzọ (maka ọgwụ nke 75 mg).

Mbadamba ụrọ a kpụrụ akpụ, ya na biconvex dị n’elu ala, nwere ihe mkpuchi fim nke ihe na-acha ọcha ma ọ bụ ihe fọrọ nke nta ka ọ bụrụ nke na-acha ọcha na ihe osise ahụ “159” n’otu akụkụ na “H” n’akụkụ nke ọzọ (maka onunu ogwu nke 150 mg).

Mbadamba ụrọ a kpụrụ akpụ, ya na biconvex dị n’elu ala, nwere ihe mkpuchi fim nke ihe na-acha ọcha ma ọ bụ ihe fọrọ nke nta ka ọ bụrụ nke na-acha ọcha nwere “Mpempe akwụkwọ” 160 n’otu akụkụ na “H” n’akụkụ nke ọzọ (maka onunu ogwu nke 300 mg).

Fogwe aka agha

Ọgwụ ndị na-emetụta sistemụ renin-angiotensin. Ndi Angagonensin II ndi ngbo. Irbesartan

ATX Koodu C09CA04